OZ 101

Drug Profile

OZ 101

Alternative Names: OZ-101

Latest Information Update: 21 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OzStar Therapeutics
  • Class Antihyperglycaemics; Carbohydrates; Sulfonylureas
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2014 Preclinical trials in Type-2 diabetes mellitus in Australia (PO)
  • 28 Jul 2014 OzStar Therapeutics plans a phase II trial for Type-2 diabetes mellitus (Adjunctive treatment) in Australia (ACTRN12614000836639)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top